Michaowicz J, Wuka A, Cyrkler M, Maczak A, Siciska P, Mokra K
Tirzepatide (same active ingredient as Mounjaro and Zepbound ) has become a sought after treatment of choice after results reported 15% to 18% weight loss findings during clinical trials (very similarly to Semaglutide)
Food and Drug Administration (FDA) in 2014 for treating type 2 diabetes under the brand name Trulicity.[5,6] Semaglutide was FDA-approved to treat type 2 diabetes and marketed as Ozempic (approved in 2017) and Rybelsus (approved in 2019).[7-10] Additionally, Trulicity and Ozempic are approved to reduce the risk of major cardiovascular events (such as heart attack and stroke) in adults with type 2 diabetes who have established cardiovascular disease.[6,8] Both dulaglutide and semaglutide medications are indicated to be used in combination with diet and exercise in type 2 diabetics.[6,8,10] Then, in 2021, semaglutide, under the brand name Wegovy, became the first drug since 2014 to be approved by the FDA for chronic weight management in obese and overweight patients with diet and exercise.[7,11] Overweight patients must have at least one weight-related condition, such as high blood pressure or type 2 diabetes
Is it possible to explore new anticancer treatment targeting component(s) of the carnitine system
If appropriate for weight-loss and tolerability goals, step up gradually (7.5 10 12.5 15 mg) at ~4-week intervals under medical supervision
phaseolina has not been reported to date
